Rimonabant Acomplia

This articol is for our old customers  who were used to come to our site and buy maternity dresses.Maybe you think  what we did is strage and it’s not normal to go from selling dresses to Rimonabant.But the fact is that we did it for our customers and for all women that recentlly gave birth.

  The explanation is simple:our old buyers know were to find us and can continue tell their friend about us,so we thought it would be better to go to the next level.Our dresses are for pregnang women and until now we were concerned for them only until they gave birth,so we thought that it would be better to help them after that moment too. 

The period after you bring a baby to this world is beautiful but in the same time womens get depressed because of the way they look and they can’t enjoy that amazing period from their lifes.

We are telling you all give because it happened to us also and it’s really hard to accept the way you look.

  So,we consider that Rimonabant it’s really a solution..Rimonabant it’s a weight loss pill and it has the best result.,but more about this pill you will find out in our next posts.I used this pill and the results are amaizing I lost 25 pounds in 2 months!!!Among that we have customers that used it and were very pleased. 

For all this reasons we decided that the best thing we could do is telling you about Rimonabant and it’s amaizing results.

You can buy Rimonabant under the brand name Acomplia.

  I hope our explanation are fine from your point of view,because we did our best to tell you why we are using now the old store not for selling maternity dresses(like we used to),but for promoting this miracle solution for you :Rimonabant.

Acomplia is a French diet drug that is produces by  Sanofi-Aventis (a popular drug company). This diet drug has proven itself to be strongly effective in helping people to lose weight. Although this medicine is generally prescribed to treat obesity, it can also be used in order to reduce the harmful risk factors that are related with weight and that could trigger severe medical desise (such as heart disorders).

Acomplia represents one of the latest and indeed one of the best ways for controlling body weight. Acomplia acts by being a cannabinoid receptor antagonist. This means that Acomplia prevents the normal action of endogenous cannabinoid located in the brain from stimulating the so-called CB1 receptors. It seems  that these receptors stimulate the desire to eat and because of that when they are “subdued” so is the need to eat. 

This diet drug first appeared in European Union pharmacies in 2006 and has quickly increased its popularity from that moment until now. Lots of clinical trials have proven that one of three patiens who have followed a treatment with Acomplia has been able to lose 25% of their body weight without gaining any kilos for in the next few years. Most people who have been treated with this drug lost  5 inches (48 pounds).

Acomplia also showed dramatic improvements also were reported in lipid profile with a 23% increase in HDL-cholesterol (good cholesterol) and a 15% decrease in triglycerides.

Improvements in glucose tolerance and insulin levels were also reported. Approximately half of the people diagnosed and participated at the studies with metabolic syndrome, who received the higher 20 mg daily dose of Acomplia, no longer had this condition at the conclusion of the trial.

If you buy Acomplia,the pill does not only facilitate the ability to control your weight, but fosters the ability to fend off weight gain.

Rimonabant, discovered and produced by French pharmaceutical firm Sanofi-Avensis, is a new drug thas has shown great promise in trials for the treatment of obesity and related metabolic risk factors.

Rimonabant works by blocking the CB1 receptor, one of two receptors found in a newly described physiological system called the Endocannabinoid System (EC System), believed to play a critical role in the regulation of food intake and energy expenditure and it also  helping by normalizing the over-activation of the EC system and making hunger or cigarette pangs more manageable.

Along with effective weight loss, Rimonabant discourages bad habits like smoking. It is also an anti-smoking pill and improves HDL(good cholesterol) and triglyceride levels. This benefits diabetes and heart conditions. Usual dosage recommended is 20mg per day based on the advise of your doctor depending on your health.

Rimonabant is widely available outside the United States, including in Eurolpe for a log time now, but Sanofi Aventis pulled it back from consideration by the U.S. FDA last summer after an agency advisory panel unanimously expressed concern over the drug’s psychiatric side-effects and they refused to approve it.

Some of the side effects that can develop due to Rimonabant usage are such as insomnia, nervousness, dry mouth,unpleasant taste in the mouth. Don’t worry about Rimonabant Acomplia’s side effects, they are natural as for any diet because of the changes in your metabolism,but if you suffer from depression you should not take it.

 It is always advisable to talk to your doctor as and when you experience these or any other side effects.

 Rimonabant is a great weight loss pill for obese patients ,so buy Rimonabant online and start reducing weight today. 

QUESTIONS AND ANSWERS ON THE SAFETY OF Acomplia (RIMONABANT)
As part of its continuous monitoring of medicines, the European Medicines Agency (EMEA) has
reviewed the available information on the safety of Rimonabant Acomplia (rimonabant), particularly on the
medicine’s psychiatric safety. It has concluded that Rimonabant Acomplia’s benefits continue to outweigh its
risks, but that patients with ongoing major depression or who are receiving antidepressant treatment
should not be prescribed Rimonabant Acomplia and that some of the warnings in the medicine’s prescribing
information should be strengthened.
What is Rimonabant Acomplia?
Rimonabant Acomplia is a medicine containing the active substance rimonabant. It is used together with diet
and exercise to reduce weight in adult patients who are:
• obese (very overweight) with a body mass index (BMI) greater or equal to 30 kg/m
2
, or,
• overweight (BMI greater or equal to 27 kg/m
2
) and also have other risk factors, such as type 2
diabetes or dyslipidaemia (abnormal levels of fat in their blood).
The active substance in Rimonabant Acomplia, is a cannabinoid receptor antagonist. It acts by
blocking a specific type of receptor called cannabinoid type 1 (CB1) receptors. These receptors are
found in the nervous system and are part of the system that the body uses to control food intake. By
blocking the receptors, rimonabant can help patients to reduce food intake and to lose weight. The
receptors are also found in peripheral tissues including adipocytes (fat cells).
Rimonabant Acomplia is authorised in the European Union/European Economic Area, and is marketed in 13
European countries. Rimonabant is also authorised as ZIMULTI, but this product is not marketed in
the European Union.
Why has the EMEA reviewed the medicine?
Rimonabant Acomplia received a positive opinion from the EMEA’s Committee for Medicinal Products for
Human Use (CHMP) on 27 April 2006, and a marketing authorisation from the European Commission
on 19 June 2006. During the approval procedure, the main safety issue identified with the medicine
was psychiatric side effects, especially depression. The company that makes Rimonabant Acomplia was
requested to monitor these side effects.
In June 2007, as part of its continuous monitoring of the safety of this medicine, the CHMP requested
all available information on the psychiatric safety of Rimonabant Acomplia from sanofi-aventis. The review of
this information was finalised at the CHMP meeting of 16-19 July 2007.
Which data has the CHMP reviewed?
The review included information on the psychiatric safety of Rimonabant Acomplia, focusing on cases of
depression in patients taking the medicine, including suicidal ideation (thoughts about committing
suicide) and suicide attempts. This information came both from the company’s monitoring of the use
of the medicine from its launch until 18 June 2007, and from five studies involving 781 patients taking
Rimonabant Acomplia, which have been completed since Rimonabant Acomplia was granted marketing authorisation.
What were the conclusions of the CHMP?
The CHMP concluded that the benefits of Rimonabant Acomplia continue to outweigh its risks, except in
patients with ongoing major depression and/or taking antidepressants.
Page 2
It concluded that the risk of depression is approximately doubled in patients taking Rimonabant Acomplia,
compared to obese or overweight patients not taking the medicine. In a small minority of cases, this
could lead to suicidal ideation or even suicide attempts. This doubling of the risk of depression occurs
in all types of patients; however, this risk may be increased in patients with a past history of
depression. Although this pattern of side effects is similar to what was seen during the approval
procedure of the medicine, the CHMP concluded that this increased risk is of concern, since
Rimonabant Acomplia is now being used in patients with a history of psychiatric events. This could result in
patients with depression being at risk of their disease getting worse.
The CHMP also noted that too many patients are taking Rimonabant Acomplia at the same time as
antidepressants, even though Rimonabant Acomplia is not recommended for use in patients also taking
antidepressants.
Therefore, the CHMP recommended the following changes to the medicine’s prescribing information:
• upgrading to a contraindication the warning on the use of Rimonabant Acomplia in patients with
ongoing major depression or taking antidepressants. This means that Rimonabant Acomplia must no
longer be used in these patients,
• adding a warning that treatment with Rimonabant Acomplia should be stopped if a patient develops
depression,
• including additional information on the psychiatric safety of Rimonabant Acomplia.
The Committee also requested that the company provides a letter to be sent to healthcare providers
explaining the changes in recommendations of use for Rimonabant Acomplia.
What is the advice to patients and prescribers?
• Doctors should only prescribe Rimonabant Acomplia according to the updated prescribing information.
• Patients and their family should be aware of the risk of depression in patients taking Rimonabant Acomplia,
and that patients should not take Rimonabant Acomplia if they are taking an antidepressant.
• Patients who start to experience symptoms of depression while taking Rimonabant Acomplia should consult
their doctor.
• Patients who are taking Rimonabant Acomplia and have questions or concerns should talk to their doctor or
pharmacist.